N@N

Dyax Corp. to Host Third Quarter 2010 Earnings Call and Webcast

^{Published on 2010-10-20 04:10:42 - Market Wire}
 

CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--Dyax Corp. (NASDAQ:[ DYAX ]) will host a webcast and conference call, including an open question and answer session, Wednesday, October 27, 2010, to discuss its financial results and company progress for the third quarter ended September 30, 2010.

A replay of the conference call will be available through November 26, 2010 and may be accessed by dialing 888-286-8010.International callers should dial 617-801-6888. The replay passcode for all callers is 20435345. The webcast will be archived on the Dyax website for an indefinite period of time.

About Dyax

Dyax is a fully integrated biopharmaceutical company focused on discovering, developing and commercializing novel biotherapeutics for unmet medical needs. The Companya™s lead product, ecallantide, has been approved under the brand name KALBITOR^® in the United States for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older.

Dyax has established partnerships worldwide to develop and commercialize ecallantide for the treatment of HAE in key regions including Japan, Europe, North Africa, the Middle East, Russia and Israel. Dyax is also exploring other potential indications for ecallantide including drug-induced angioedema and retinal vein occlusion-induced macular edema.

Ecallantide and other compounds in Dyaxa™s pipeline were identified using its patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. As part of its Licensing and Funded Research Program, Dyax leverages this technology broadly with over 70 revenue generating licenses and collaborations for therapeutic discovery, as well as for affinity separations, diagnostic imaging, and research reagents.

Dyax is headquartered in Cambridge, Massachusetts. For online information about Dyax Corp., please visit [ www.dyax.com ].